These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19291787)

  • 21. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
    Romero-Gómez M; Del Mar Viloria M; Andrade RJ; Salmerón J; Diago M; Fernández-Rodríguez CM; Corpas R; Cruz M; Grande L; Vázquez L; Muñoz-De-Rueda P; López-Serrano P; Gila A; Gutiérrez ML; Pérez C; Ruiz-Extremera A; Suárez E; Castillo J
    Gastroenterology; 2005 Mar; 128(3):636-41. PubMed ID: 15765399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Do the interferons have an antifibrotic action? The hepatologist's point of view].
    Poynard T
    Rev Med Interne; 2002 Nov; 23 Suppl 4():517s-521s. PubMed ID: 12481408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
    J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
    Valenti L; Aghemo A; Stättermayer AF; Maggioni P; De Nicola S; Motta BM; Rumi MG; Dongiovanni P; Ferenci P; Colombo M; Fargion S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
    Jiménez Macías FM; Barrero Alor F; Casado Monge PG; Ramos Lora M; Pujol de la Llave E; Ruíz-Frutos C
    Med Clin (Barc); 2015 Jun; 144(12):536-43. PubMed ID: 24726260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment.
    Noureddin M; Ghany MG
    Am J Gastroenterol; 2010 Oct; 105(10):2174-6. PubMed ID: 20927065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
    Hoefs JC; Shiffman ML; Goodman ZD; Kleiner DE; Dienstag JL; Stoddard AM;
    Gastroenterology; 2011 Sep; 141(3):900-908.e1-2. PubMed ID: 21699796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
    Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
    Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.
    Martínez-Macías RF; Cordero-Pérez P; Juárez-Rodríguez OA; Chen-López CY; Martínez-Carrillo FM; Alarcón-Galván G; Mercado-Hernández R; Muñoz-Espinosa LE
    Ann Hepatol; 2015; 14(1):36-45. PubMed ID: 25536640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
    Stasi C; Arena U; Zignego AL; Corti G; Monti M; Triboli E; Pellegrini E; Renzo S; Leoncini L; Marra F; Laffi G; Milani S; Pinzani M
    Dig Liver Dis; 2013 Oct; 45(10):840-3. PubMed ID: 23660078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Metabolic syndrome in patients with chronic hepatitis C genotype 1].
    Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP; Abdurakhmanov DT
    Vestn Ross Akad Med Nauk; 2011; (1):3-7. PubMed ID: 21400720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
    Conjeevaram HS; Kleiner DE; Everhart JE; Hoofnagle JH; Zacks S; Afdhal NH; Wahed AS;
    Hepatology; 2007 Jan; 45(1):80-7. PubMed ID: 17187406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
    Dienstag JL; Ghany MG; Morgan TR; Di Bisceglie AM; Bonkovsky HL; Kim HY; Seeff LB; Szabo G; Wright EC; Sterling RK; Everson GT; Lindsay KL; Lee WM; Lok AS; Morishima C; Stoddard AM; Everhart JE;
    Hepatology; 2011 Aug; 54(2):396-405. PubMed ID: 21520194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
    Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL;
    Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.